iX Biopharma Ltd. (SGX: 42C)
Singapore
· Delayed Price · Currency is SGD 0.0240
0.00 (0.00%)
At close: Nov 22, 2024
iX Biopharma Income Statement
Financials in millions SGD. Fiscal year is July - June.
Millions SGD. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 | 2019 - 2015 |
| Operating Revenue | 5.96 | 5.96 | 5.91 | 14.39 | 1.75 | 0.99 | Upgrade
|
| Revenue | 5.96 | 5.96 | 5.91 | 14.39 | 1.75 | 0.99 | Upgrade
|
| Revenue Growth (YoY) | 0.78% | 0.78% | -58.91% | 724.64% | 77.16% | 46.80% | Upgrade
|
| Cost of Revenue | 4.91 | 4.91 | 3.59 | 2.1 | 2.13 | 1.57 | Upgrade
|
| Gross Profit | 1.05 | 1.05 | 2.32 | 12.29 | -0.38 | -0.59 | Upgrade
|
| Selling, General & Admin | 6.71 | 6.71 | 9.04 | 9.46 | 8.3 | 8.08 | Upgrade
|
| Research & Development | 1.73 | 1.73 | 2.82 | 2.33 | 2.75 | 2.5 | Upgrade
|
| Operating Expenses | 8.54 | 8.54 | 11.86 | 11.79 | 11.05 | 10.57 | Upgrade
|
| Operating Income | -7.5 | -7.5 | -9.54 | 0.5 | -11.43 | -11.16 | Upgrade
|
| Interest Expense | -0.44 | -0.44 | -0.27 | -0.2 | -0.17 | -0.24 | Upgrade
|
| Interest & Investment Income | 0.03 | 0.03 | 0.01 | - | 0.01 | 0.09 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.08 | 0.08 | -2.77 | -1.91 | 1.8 | 0.38 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.35 | 0.35 | 1.12 | 0.74 | 1.57 | 0.96 | Upgrade
|
| EBT Excluding Unusual Items | -7.47 | -7.47 | -11.46 | -0.88 | -8.23 | -9.97 | Upgrade
|
| Gain (Loss) on Sale of Investments | -2.51 | -2.51 | 1.74 | -3.26 | - | - | Upgrade
|
| Other Unusual Items | - | - | 0.01 | 0.04 | - | -0.53 | Upgrade
|
| Pretax Income | -9.99 | -9.99 | -9.71 | -4.1 | -8.23 | -10.5 | Upgrade
|
| Income Tax Expense | 0.81 | 0.81 | -0.09 | 0.5 | 0 | - | Upgrade
|
| Earnings From Continuing Operations | -10.79 | -10.79 | -9.62 | -4.6 | -8.23 | -10.5 | Upgrade
|
| Net Income | -10.79 | -10.79 | -9.62 | -4.6 | -8.23 | -10.5 | Upgrade
|
| Net Income to Common | -10.79 | -10.79 | -9.62 | -4.6 | -8.23 | -10.5 | Upgrade
|
| Shares Outstanding (Basic) | 767 | 767 | 765 | 746 | 693 | 647 | Upgrade
|
| Shares Outstanding (Diluted) | 767 | 767 | 765 | 746 | 693 | 647 | Upgrade
|
| Shares Change (YoY) | 0.33% | 0.33% | 2.51% | 7.60% | 7.13% | 0.54% | Upgrade
|
| EPS (Basic) | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.02 | Upgrade
|
| EPS (Diluted) | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.02 | Upgrade
|
| Free Cash Flow | -6.83 | -6.83 | -8.36 | 2.92 | -8.91 | -9.3 | Upgrade
|
| Free Cash Flow Per Share | -0.01 | -0.01 | -0.01 | 0.00 | -0.01 | -0.01 | Upgrade
|
| Gross Margin | 17.59% | 17.59% | 39.24% | 85.41% | -21.89% | -59.59% | Upgrade
|
| Operating Margin | -125.78% | -125.78% | -161.41% | 3.48% | -654.96% | -1133.10% | Upgrade
|
| Profit Margin | -181.14% | -181.14% | -162.61% | -31.95% | -471.86% | -1065.89% | Upgrade
|
| Free Cash Flow Margin | -114.57% | -114.57% | -141.30% | 20.31% | -510.32% | -944.57% | Upgrade
|
| EBITDA | -7.08 | -7.08 | -9.04 | 1.15 | -10.79 | -10.52 | Upgrade
|
| EBITDA Margin | -118.88% | -118.88% | -152.93% | 7.98% | - | - | Upgrade
|
| D&A For EBITDA | 0.41 | 0.41 | 0.5 | 0.65 | 0.64 | 0.65 | Upgrade
|
| EBIT | -7.5 | -7.5 | -9.54 | 0.5 | -11.43 | -11.16 | Upgrade
|
| EBIT Margin | -125.78% | -125.78% | -161.41% | 3.48% | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.